Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Assets (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Assets for 13 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 24.54% to $20.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.1 million, a 24.54% decrease, with the full-year FY2025 number at $20.1 million, down 24.54% from a year prior.
  • Assets was $20.1 million for Q4 2025 at Ekso Bionics Holdings, down from $21.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $56.5 million in Q1 2021 to a low of $20.1 million in Q4 2025.
  • A 5-year average of $35.5 million and a median of $32.6 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: skyrocketed 233.47% in 2021, then fell 29.3% in 2023.
  • Ekso Bionics Holdings' Assets stood at $49.2 million in 2021, then decreased by 16.81% to $40.9 million in 2022, then dropped by 29.3% to $28.9 million in 2023, then dropped by 7.84% to $26.7 million in 2024, then decreased by 24.54% to $20.1 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Assets are $20.1 million (Q4 2025), $21.7 million (Q3 2025), and $23.2 million (Q2 2025).